ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.36
0.17%
US Tech 100
20,911.20
0.90%
S&P 500
6,037.88
0.72%
US Dollar vs CAD
1.43412
0.05%
Bitcoin
98,164.55
0.31%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Sage Therapeutics Inc (SAGE) Share Price

Sage Therapeutics Inc

Sage Therapeutics Inc (SAGE)

Sage Potash Corp
7.24
-0.02
(-0.28%)
Closed February 04 3:00PM
Delayed by 15 minutes
7.20
-0.04
(-0.55%)
After Hours: 6:35PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
7.20
Bid
7.08
Ask
7.83
Volume
1,601,557
7.18 Day's Range 7.31
4.62 52 Week Range 27.39
Market Cap
440.447M
Previous Close
7.26
Open
7.31
Last Trade
101
@
7.2
(formt)
Last Trade Time
Financial Volume
US$ 11,620,624
VWAP
7.2558
Average Volume (3m)
1,786,672
Shares Outstanding
61,173,263
Dividend Yield
-
PE Ratio
-0.82
Earnings Per Share (EPS)
-8.85
Revenue
86.46M
Net Profit
-541.49M

About Sage Therapeutics Inc

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical tri... Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.sagerx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Sage Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SAGE. The last closing price for Sage Therapeutics was US$7.26. Over the last year, Sage Therapeutics shares have traded in a share price range of US$ 4.62 to US$ 27.39.

Sage Therapeutics currently has 61,173,263 shares outstanding. The market capitalization of Sage Therapeutics is US$444.12 million. Sage Therapeutics has a price to earnings ratio (PE ratio) of -0.82.

Ask ADVFN Intelligence (AI)

SAGE Latest News

More News

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial...

January 28 2025
Business Wire

Form 8-K - Current report

January 27 2025
Edgar (US Regulatory)

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal

Company Board Concludes the Proposal Significantly Undervalues Sage and Believes it is Not in the Best Interest of Shareholders The Company Remains Focused on the Goal of Establishing ZURZUVAE as...

January 27 2025
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

January 21 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 21 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 21 2025
Edgar (US Regulatory)

Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference

Increased investment in ZURZUVAE to help accelerate market growth in postpartum depression with the goal of topline revenue growth in 2025 R&D and G&A expenses expected to decrease...

January 12 2025
Business Wire

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

No Shareholder Action Required at This Time Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an...

January 10 2025
Business Wire

Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 8:15 a.m. PT in San...

January 08 2025
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

December 27 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.25-3.355704697997.457.57.1414631447.30954557CS
40.8813.92405063296.327.885.44529718317.18533282CS
120.9715.5698234356.237.884.6217866726.36963947CS
26-1.58-17.99544419138.789.074.6211531996.7121099CS
52-17.26-70.564186426824.4627.394.62114395910.70277553CS
156-33.48-82.300884955840.6859.994.6291153223.15510545CS
260-61.26-89.482909728368.4698.3854.6283446833.61393633CS

SAGE - Frequently Asked Questions (FAQ)

What is the current Sage Therapeutics share price?
The current share price of Sage Therapeutics is US$ 7.20
How many Sage Therapeutics shares are in issue?
Sage Therapeutics has 61,173,263 shares in issue
What is the market cap of Sage Therapeutics?
The market capitalisation of Sage Therapeutics is USD 444.12M
What is the 1 year trading range for Sage Therapeutics share price?
Sage Therapeutics has traded in the range of US$ 4.62 to US$ 27.39 during the past year
What is the PE ratio of Sage Therapeutics?
The price to earnings ratio of Sage Therapeutics is -0.82
What is the cash to sales ratio of Sage Therapeutics?
The cash to sales ratio of Sage Therapeutics is 5.12
What is the reporting currency for Sage Therapeutics?
Sage Therapeutics reports financial results in USD
What is the latest annual turnover for Sage Therapeutics?
The latest annual turnover of Sage Therapeutics is USD 86.46M
What is the latest annual profit for Sage Therapeutics?
The latest annual profit of Sage Therapeutics is USD -541.49M
What is the registered address of Sage Therapeutics?
The registered address for Sage Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Sage Therapeutics website address?
The website address for Sage Therapeutics is www.sagerx.com
Which industry sector does Sage Therapeutics operate in?
Sage Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAPTCaptiVision Inc
US$ 1.024
(133.26%)
246M
QNTMQuantum Biopharma Ltd
US$ 6.70
(110.69%)
78.56M
LTRYLottery com Inc
US$ 0.58
(85.90%)
129.21M
CPIXCumberland Pharmaceutical Inc
US$ 3.7801
(77.47%)
18.49M
INKTMiNK Therapeutics Inc
US$ 12.08
(53.69%)
350.86k
OMGAOmega Therapeutics Inc
US$ 0.1473
(-69.25%)
11.71M
VIRXViracta Therapeutics Inc
US$ 0.0352
(-54.76%)
6.33M
CYNCYNGN Inc
US$ 0.0708
(-39.44%)
137.42M
UPCUniverse Pharmaceuticals Inc
US$ 0.2663
(-36.20%)
1.9M
CSAICloudastructure Inc
US$ 12.98
(-31.68%)
57.03k
NVDANVIDIA Corporation
US$ 118.65
(1.71%)
247.88M
CAPTCaptiVision Inc
US$ 1.024
(133.26%)
245.99M
PLTRPalantir Technologies Inc
US$ 103.83
(23.99%)
212.8M
RGTIRigetti Computing Inc
US$ 13.71
(1.78%)
150.63M
CYNCYNGN Inc
US$ 0.0708
(-39.44%)
134.64M

SAGE Discussion

View Posts
Monksdream Monksdream 10 months ago
SAGE over $10
👍️0
everton44 everton44 1 year ago
SAGE going to 36 dollars, every article and financial companies downgrading SAGE yet it goes up big. HAHAHA
👍️0
gail gail 1 year ago
i dont know anything about…

…

shorting. i am a simpleton, lol, i just trade like a normal trader.

not in this one, but made a bundle on my last few trades, including ttoo today. weeee!!
👍️0
everton44 everton44 1 year ago
we are all short selling the piss out of this now, come on board
👍️0
gail gail 1 year ago
so, they got approved yet…

..

it dropped huge today? im not in it but watching.
👍️0
AGORDON AGORDON 2 years ago
FDA approved Zuranolone for PPD. CRL for Major Depressive.
👍️0
AGORDON AGORDON 2 years ago
The FDA is still considering whether to approve zuranolone for clinical depression in addition to postpartum depression, but did not issue a decision on that indication.
👍️0
budgetthis budgetthis 3 years ago
I was gonna burn some SAGE today, in a therapeutic manner, like they do on Yellowstone to ward off evil spirits.

But no need……elevators going up today……lol.

$$ SAGE $$
👍️0
CjMitts CjMitts 3 years ago
Called the pump, How'd I know, garbby 10q report, RSI divergence. will be loading this at the bottom though with the money I make from this short, the potential of this companies pipeline is enormous.
👍️0
CjMitts CjMitts 3 years ago
Boom
👍️0
CjMitts CjMitts 3 years ago
Dont be fooled by the pump. Will be loading between 34-26. Surprised there's no talk on this page regarding the potential of this companies pipeline.
👍️0
thumper1 thumper1 5 years ago
im out high 68.eom
👍️0
thumper1 thumper1 5 years ago
bought 67.11. we will see
👍️0
NYCPuglet NYCPuglet 5 years ago
Sold at 77. Thank god. Lol.
👍️0
NYCPuglet NYCPuglet 5 years ago
In 1000 @ at 73. Easy profit flipper here. Very big whales behind this company.
👍️0
Daysinn4610 Daysinn4610 5 years ago
Ceo cfo cso all buying shares https://www.gurufocus.com/news/999044/sage-therapeutics-inc-sage-president--ceo-jeffrey-m-jonas-bought-481500-of-shares
👍️0
Daysinn4610 Daysinn4610 5 years ago
Some sage news https://www.streetinsider.com/dr/news.php?id=16261148
👍️0
keekee keekee 5 years ago
Lol....brig6and early. Crossing $80 today? The $125 may actually happen by the end if the month? We will see.
👍️0
keekee keekee 5 years ago
Seen this...though it is going to be just a few days apart. Congrats to BULLS....and I sure hope those that jumped in to short because I highlighted the stock GO BANKRUPT!!!
👍️0
keekee keekee 5 years ago
$74 now. Everyone that shorted past week is now in red. And it will get even more painful going forward. Sorry, losers!
👍️0
keekee keekee 5 years ago
$3 to $4 a day is fine for now. In a week or so we wi6see doing more than that number as we race back towards $125. When I saw BUY...and some.fools sell, all I think of is, Who the hell is their father!!!! Who do they get information from...David Einhorn or who? He just did 34% loss last year and is on track to be smothered again with the TSLA outperformance. We are headed up....Intelsat, SAGE, ASLN, FRAN, And a host of others.
👍️0
keekee keekee 5 years ago
We're headed to $80 very likely today. It's a one way train here m.j till.$100.
👍️0
Biobonic Biobonic 5 years ago
Post-hoc analysis revealed that in the MOUNTAIN Study, approximately 9% of patients in the SAGE-217 30 mg group had no measurable drug concentration, consistent with non-compliance in taking SAGE-217

In the 30mg group, 192 received the medication at the onset of the trial.

9% would approximate: 17 participants.

The trial had 28 participants withdraw by day 42. (14%) a significant number, especially since there was a good measure of efficacy.



👍️0
RJ Trotts RJ Trotts 5 years ago
I got out with 4.50 per share profit, we are both happy, enjoy your weekend. Hoping to find more winners next week.
👍️0
Nebuchadnezzar Nebuchadnezzar 5 years ago
Caught this falling knife yesterday, out up $6.45 profit
👍️0
keekee keekee 5 years ago
Watch when this stock went down from $68 yestersay. That was when I intentionally posted that I loaded. They came.and brought the it down. I reloaded. And they sre still here. Ditto for PTGX, 1, PRTY, AIHS, ASLN, AFH, SLDB, AFI, CBAY, ATIS. and a couple more. The have shorted most of these floats over 100% but still.manages tonhang on because folks have no idea that these stocks will fly double or triple. But check those out and good luck. They are mostly DOUBLERS in a month or two.
👍️0
keekee keekee 5 years ago
There are folks that short anything I buy. They are the idiots holding this down. CV lick on my name to see other stocks we play opposite. They have money but no brain. Investor money. They will shi ort anything I posted that I bought under any circumstance. They are the knes here. Ignote the selling and load. This will fly!!!
👍️0
T695 T695 5 years ago
I think we at resistance in the $66 are. The entire market will be over bought in a minute and this will sell off hard
👍️0
keekee keekee 5 years ago
Minimum close today will be $70. I will take that..from $54 and lower entry yesterday. This one is as easy...easy. will likely be trending toward $100 by month end
👍️0
T695 T695 5 years ago
Looks like my first outlook was the right one
👍️0
VictorMasonIsRight VictorMasonIsRight 5 years ago
SAGE test compromised by 9 non compliant patients?
Otherwise would have met all benchmarks?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152647122
👍️0
RJ Trotts RJ Trotts 5 years ago
up in pre-market right now, here's to hoping it bounces nicely
👍️0
T695 T695 5 years ago
On second thoughts, might me another 20% or so haircut today after all the downgrades
👍️0
T695 T695 5 years ago
It’s way over sold, but still could fall to 50ish
👍️0
T695 T695 5 years ago
I’m thinking we get a bounce from here to $66-67ish, when if it hits there it may either run back to low 70’s or pull back to 50’s then run to $70’s.... either way I see lows 50’s and lows 70’s as short term bottom and top
👍️0
RJ Trotts RJ Trotts 5 years ago
May add some here after hours, and see if it will bounce tomorrow. Best to all here. Hoping it is oversold!
👍️0
keekee keekee 5 years ago
Unfortunately, I brought them over..I mean the heavy sellers. These guys are blind in their rabid quest to trade against me. But I create losses for them. That is my mission now. We will see $100. The clueless sellers know it too!
👍️0
keekee keekee 5 years ago
Will cross $80 tom8. Must $100 by next week. The fools selling are misguided
👍️0
T695 T695 5 years ago
Might see by EOD
👍️0
keekee keekee 5 years ago
This thing may actually return to $1.25 by year end. That would be over 200% for.me. lol. In at $54 and lower..pre.
👍️0
keekee keekee 5 years ago
Loaded premkt at $53. Must get $100. Drug did not fail if you factor in the 9 candidates that did not take it. $100..let's go
👍️0
T695 T695 5 years ago
Make take a nibble at $50
👍️0
altruism altruism 5 years ago
4 according to 1 news source I saw
👍️0
Awl416 Awl416 5 years ago
How many billions that she’s off the market cap - wow
👍️0
NYCPuglet NYCPuglet 6 years ago
Such an easy predictable stock.
👍️0
cvm101 cvm101 6 years ago
So this Leerink Swann call of 1/7 is looking pretty idiotic now as stock crosses $144.00
Earlier they had downgraded and lowered target price to $80.00

Sage Therapeutics stock price target raised to $90 from $80 at Leerink
👍️0
NYCPuglet NYCPuglet 6 years ago
Once again it drops. Gotta love this flipper.
👍️0
NYCPuglet NYCPuglet 6 years ago
Wish I had funds last week to throw in. I sensed a big pop was coming.
👍️0
cvm101 cvm101 6 years ago
Well it has been - but with the approval to market the new drug its less a speculation and more an investable company. Longer term its worth $200. Most analyst target prices are in that area.
👍️0
NYCPuglet NYCPuglet 6 years ago
Yep. This is an insane flipper stock.
👍️0

Your Recent History

NASDAQ
SAGE
Sage Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads